SCHEMBL4388230

SCHEMBL4388230

N#Cc1cccc(CON=C2CCN(S(=O)(=O)c3ccc(OC(F)(F)F)cc3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ADAM17 P78536 4/20 0.41
MMP1 P03956 1/20 0.41
GPR6 P46095 1/20 0.40
AKR1C3 P42330 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP14 P50281 1/20 0.37
CYP2C9 P11712 1/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP13 P45452 1/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4379092 0.89 MRGPRX4 (0.45) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL4383840 0.89 MEN1 (0.46) MEN1KMT2AADAM17MMP1GPR6
SCHEMBL13589015 0.89 CYP3A4 (0.43) MEN1KMT2AADAM17MMP1AKR1C3
SCHEMBL4380262 0.88 LMNA (0.48) ADAM17MMP1LMNAALDH1A1HTT
SCHEMBL8225081 0.88 RORC (0.43) MEN1KMT2AADAM17MMP1ALDH1A1
SCHEMBL4380271 0.88 MEN1 (0.42) MEN1KMT2AGPR6
SCHEMBL4386136 0.87 ADAM17 (0.43) ADAM17MMP1MAOAMAOBMMP14
SCHEMBL4385773 0.87 ADAM17 (0.43) MEN1KMT2AADAM17MMP1MAOA
SCHEMBL4391254 0.86 ADAM17 (0.44) ADAM17MMP1MAOAMAOBADAMTS4
SCHEMBL4380572 0.86 MEN1 (0.43) MEN1KMT2AADAM17AKR1C3MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 MEN1 3694/4885KMT2A 2079/4885ADAM17 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.